1
|
Hahn C, Budhram A, Alikhani K, AlOhaly N, Beecher G, Blevins G, Brooks J, Carruthers R, Comtois J, Cowan J, de Robles P, Hébert J, Kapadia RK, Lapointe S, Mackie A, Mason W, McLane B, Muccilli A, Poliakov I, Smyth P, Williams KG, Uy C, McCombe JA. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci 2024:1-21. [PMID: 38312020 DOI: 10.1017/cjn.2024.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2024]
Abstract
Autoimmune encephalitis is increasingly recognized as a neurologic cause of acute mental status changes with similar prevalence to infectious encephalitis. Despite rising awareness, approaches to diagnosis remain inconsistent and evidence for optimal treatment is limited. The following Canadian guidelines represent a consensus and evidence (where available) based approach to both the diagnosis and treatment of adult patients with autoimmune encephalitis. The guidelines were developed using a modified RAND process and included input from specialists in autoimmune neurology, neuropsychiatry and infectious diseases. These guidelines are targeted at front line clinicians and were created to provide a pragmatic and practical approach to managing such patients in the acute setting.
Collapse
Affiliation(s)
- Christopher Hahn
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | - Adrian Budhram
- Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada
- Department of Pathology and Laboratory Medicine, Western University, London Health Sciences Centre, London, ON, Canada
| | - Katayoun Alikhani
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | - Nasser AlOhaly
- Division of Neurology, University of Toronto, Toronto, ON, Canada
| | - Grayson Beecher
- Division of Neurology, University of Alberta, Edmonton, AB, Canada
| | - Gregg Blevins
- Division of Neurology, University of Alberta, Edmonton, AB, Canada
| | - John Brooks
- Division of Neurology, University of Toronto, Toronto, ON, Canada
| | - Robert Carruthers
- Division of Neurology, University of British Columbia, Vancouver, BC, Canada
| | - Jacynthe Comtois
- Neurosciences, Universite de Montreal Faculte de Medecine, Montreal, QC, Canada
| | - Juthaporn Cowan
- Division of Infectious Diseases, Department of Medicine Ottawa Hospital, Ottawa, ON, Canada
| | - Paula de Robles
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - Julien Hébert
- Division of Neurology, University of Toronto, Toronto, ON, Canada
| | - Ronak K Kapadia
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | - Sarah Lapointe
- Neurosciences, Universite de Montreal Faculte de Medecine, Montreal, QC, Canada
| | - Aaron Mackie
- Department of Psychiatry, University of Calgary, Calgary, AB, Canada
| | - Warren Mason
- Division of Neurology, University of Toronto, Toronto, ON, Canada
| | - Brienne McLane
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Department of Psychiatry, University of Calgary, Calgary, AB, Canada
| | | | - Ilia Poliakov
- Division of Neurology, University of Saskatchewan College of Medicine, Saskatoon, SK, Canada
| | - Penelope Smyth
- Division of Neurology, University of Alberta, Edmonton, AB, Canada
| | | | - Christopher Uy
- Division of Neurology, University of British Columbia, Vancouver, BC, Canada
| | | |
Collapse
|
2
|
Koch MW, Moral E, Brieva L, Mostert J, Strijbis EMM, Comtois J, Repovic P, Bowen JD, Wolinsky JS, Lublin FD, Cutter G. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset. Mult Scler 2023; 29:1776-1785. [PMID: 37830451 PMCID: PMC10687796 DOI: 10.1177/13524585231202320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 08/23/2023] [Accepted: 09/04/2023] [Indexed: 10/14/2023]
Abstract
BACKGROUND Clinical relapses are the defining feature of relapsing forms of multiple sclerosis (MS), but relatively little is known about the time course of relapse recovery. OBJECTIVE The aim of this study was to investigate the time course of and patient factors associated with the speed and success of relapse recovery in people with relapsing-remitting MS (RRMS). METHODS Using data from CombiRx, a large RRMS trial (clinicaltrials.gov identifier NCT00211887), we measured the time to recovery from the first on-trial relapse. We used Kaplan-Meier survival analyses and Cox regression models to investigate the association of patient factors with the time to unconfirmed and confirmed relapse recovery. RESULTS CombiRx included 1008 participants. We investigated 240 relapses. Median time to relapse recovery was 111 days. Most recovery events took place within 1 year of relapse onset: 202 of 240 (84%) individuals recovered during follow-up, 161 of 202 (80%) by 180 days, and 189 of 202 (94%) by 365 days. Relapse severity was the only factor associated with relapse recovery. CONCLUSION Recovery from relapses takes place up to approximately 1 year after the event. Relapse severity, but no other patient factors, was associated with the speed of relapse recovery. Our findings inform clinical practice and trial design in RRMS.
Collapse
Affiliation(s)
- Marcus W Koch
- Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada
| | - Ester Moral
- Department of Neurology, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain
| | - Luis Brieva
- Neuroimmunology Group, Department of Medicine, University of Lleida-IRBLleida, Lleida, Spain Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - Jop Mostert
- Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands
| | - Eva MM Strijbis
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Jacynthe Comtois
- Department of Medicine, Neurology Service, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
| | - Pavle Repovic
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA
| | - James D Bowen
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA
| | - Jerry S Wolinsky
- Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
| | - Fred D Lublin
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Gary Cutter
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
3
|
Strijbis EM, Coerver E, Mostert J, van Kempen ZLE, Killestein J, Comtois J, Repovic P, Bowen JD, Cutter G, Koch M. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2023; 94:792-799. [PMID: 37173129 DOI: 10.1136/jnnp-2022-330887] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 04/18/2023] [Indexed: 05/15/2023]
Abstract
BACKGROUND Focal inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) diminishes with increasing age. Here we use patient-level data from randomised controlled trials (RCTs) of natalizumab treatment in RRMS to investigate the association of age and inflammatory disease activity. METHODS We used patient-level data from the AFFIRM (natalizumab vs placebo in relapsing-remitting MS, NCT00027300) and SENTINEL (natalizumab plus interferon beta vs interferon beta in relapsing remitting MS, NCT00030966) RCTs. We determined the proportion of participants developing new T2 lesions, contrast-enhancing lesions (CELs) and relapses over 2 years of follow-up as a function of age, and investigated the association of age with time to first relapse using time-to-event analyses. RESULTS At baseline, there were no differences between age groups in T2 lesion volume and number of relapses in the year before inclusion. In SENTINEL, older participants had a significantly lower number of CELs. During both trials, the number of new CELs and the proportion of participants developing new CELs were significantly lower in older age groups. The number of new T2 lesions and the proportion of participants with any radiological disease activity during follow-up were also lower in older age groups, especially in the control arms. CONCLUSIONS Older age is associated with a lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS. Our findings inform the design of RCTs, and suggest that patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS.
Collapse
Affiliation(s)
- Eva M Strijbis
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Eline Coerver
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Jop Mostert
- Department of Neurology, Rijnstate Hospital Arnhem, Arnhem, The Netherlands
| | - Zoé L E van Kempen
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Joep Killestein
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Jacynthe Comtois
- Department of Medicine, Neurology service, Maisonneuve-Rosemont Hospital, Montreal, Québec, Canada
| | - Pavle Repovic
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA
| | - James D Bowen
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA
| | - Gary Cutter
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Marcus Koch
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
4
|
Koch MW, Repovic P, Mostert J, Bowen JD, Comtois J, Strijbis E, Uitdehaag B, Cutter G. Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. Eur J Neurol 2023; 30:2761-2768. [PMID: 37306560 DOI: 10.1111/ene.15920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/11/2023] [Accepted: 06/08/2023] [Indexed: 06/13/2023]
Abstract
BACKGROUND AND PURPOSE The timed 25-foot walk (T25FW) and nine-hole peg test (NHPT) exhibit random variability in the short term. A threshold of ≥20% change from baseline has been used to indicate true disability change, but other threshold definitions may be better suited to exclude false and include true change events. The aim of this study was to use patient-level original trial data to investigate the short-term variation in T25FW and NHPT, and to compare its extent with disability change at 12-month follow-up in people with primary progressive multiple sclerosis (PPMS). METHODS We used original patient-level data from PROMISE, a large PPMS trial. In this trial, three separate T25FW and NHPT measurements were performed 1 week apart during screening. We used these repeated measures to describe the extent of short-term variation. We used binary logistic regression models to investigate the association between screening characteristics and unacceptable short-term variation. RESULTS The traditional 20% threshold excluded a reasonable number of false change events, while also yielding a large number of change events at follow-up. Increasing index values on the T25FW and NHPT were associated with higher short-term variation. CONCLUSIONS The traditional ≥20% change threshold for the T25FW and NHPT represents a reasonable compromise between reducing the number of false change events and achieving the largest number of change events in people with PPMS. Our analyses inform the design of clinical trials in PPMS.
Collapse
Affiliation(s)
- Marcus W Koch
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Pavle Repovic
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA
| | - Jop Mostert
- Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands
| | - James D Bowen
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA
| | - Jacynthe Comtois
- Department of Medicine, Neurology service, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
- Département de neurosciences, Faculté de médecine, Université de Montréal, Montreal, Quebec, Canada
| | - Eva Strijbis
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Bernard Uitdehaag
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Gary Cutter
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
5
|
Koch MW, Repovic P, Mostert J, Bowen JD, Comtois J, Strijbis E, Uitdehaag B, Cutter G. The nine hole peg test as an outcome measure in progressive MS trials. Mult Scler Relat Disord 2023; 69:104433. [PMID: 36462470 DOI: 10.1016/j.msard.2022.104433] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2022] [Revised: 11/07/2022] [Accepted: 11/23/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND The nine-hole peg test (NHPT) is the outcome measure with the least change in secondary and primary progressive MS (SPMS and PPMS) trials. The Standard NHPT is defined as the average of four measurements, two in each hand. Little is known about the performance of alternative NHPT scoring methods as longitudinal outcome measures in progressive MS. Non-ambulatory people with progressive MS are now generally excluded from clinical trials, and there is little information on longitudinal NHPT change in this patient group. In this investigation, we used patient-level data from two large randomized controlled trials in progressive MS to explore alternative NHPT scoring methods and NHPT change in non-ambulatory people with progressive MS. METHODS We used patient-level data from the ASCEND (SPMS, n = 889) and PROMISE (PPMS, n = 943) clinical trials to compare significant change on the Standard NHPT with the alternatives dominant hand (DH), non-dominant hand (NDH), and either hand (EH) NHPT in ambulatory and non-ambulatory trial participants. RESULTS The Standard NHPT changed slowly and showed few worsening events, as did the DH and NDH alternatives. Using the EH NHPT resulted in a substantial increase of worsening events. Non-ambulatory trial participants with PPMS experienced more NHPT worsening than ambulatory participants, especially when using the EH NHPT. CONCLUSION Using the EH NHPT yielded substantially more worsening events in people with progressive MS. Clinical trials in non-ambulatory people may be possible with the NHPT as the primary outcome measure. More research into the precision of these measures in this patient group is necessary.
Collapse
Affiliation(s)
- Marcus W Koch
- Department of Clinical Neurosciences, University of Calgary, Canada; Department of Community Health Sciences, University of Calgary, Canada
| | - Pavle Repovic
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, USA
| | - Jop Mostert
- Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands
| | - James D Bowen
- Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, USA
| | - Jacynthe Comtois
- Department of Medicine, Neurology service, Hôpital Maisonneuve-Rosemont, Montreal, Canada; Département de neurosciences, Faculté de médecine, Université de Montréal, Montreal, Canada
| | - Eva Strijbis
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Bernard Uitdehaag
- Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Gary Cutter
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, USA
| |
Collapse
|
6
|
Comtois J, Camara-Lemarroy CR, Mah JK, Kuhn S, Curtis C, Braun MH, Tellier R, Burton JM. Longitudinally extensive transverse myelitis with positive aquaporin-4 IgG associated with dengue infection: a case report and systematic review of cases. Mult Scler Relat Disord 2021; 55:103206. [PMID: 34418736 DOI: 10.1016/j.msard.2021.103206] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Revised: 07/03/2021] [Accepted: 08/06/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Neuromyelitis Optica Spectrum Disorder can be associated with parainfectious and post-infectious triggers. Dengue virus infection is one of the most common arbovirus infections in the world, and may present with neurological manifestations. OBJECTIVES We present a case of DENV-associated with LETM and positive aquaporin-4 IgG, and a systematic review of published cases. METHODS Medline (Ovid) and PubMed were search through June 2021, for case reports, series and observational studies that described patients with DENV-associated LETM and/or NMOSD. RESULTS An adolescent girl who had recently immigrated from a Dengue-endemic region presented with a LETM with high positive AQP4-IgG titer and seropositive DENV IgM/IgG antibodies. She responded well to steroids and subsequently started maintenance rituximab for her NMOSD diagnosis. LITERATURE REVIEW 22 publications describing 27 patients met inclusion criteria. In addition to this case, three published cases met current criteria for NMOSD with serological evidence of acute DENV infection. CONCLUSIONS It is unknown whether there is a pathophysiological association between DENV infection and NMOSD. Regardless, if an immune-mediated event is suspected, particularly NMOSD, appropriate immunotherapy should be considered early. Decision regarding long term immunotherapy may depend on index of suspicion of true NMOSD, and this is where AQP4-IgG status and follow-up is helpful.
Collapse
Affiliation(s)
- Jacynthe Comtois
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medicine, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada; Department of neurosciences, Faculty of medicine, University of Montreal, Montreal, Quebec, Canada
| | - Carlos R Camara-Lemarroy
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
| | - Jean K Mah
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Susan Kuhn
- Division of Infectious Diseases, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Colleen Curtis
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Marvin H Braun
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Raymond Tellier
- Division of Infectious diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Jodie M Burton
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
7
|
Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, Bauer PR, Kwon CS, Jetté N, Josephson CB, Keezer MR. Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis. Neurology 2021; 96:805-817. [PMID: 33722992 DOI: 10.1212/wnl.0000000000011839] [Citation(s) in RCA: 107] [Impact Index Per Article: 35.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 01/29/2021] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To evaluate the incidence and prevalence of drug-resistant epilepsy (DRE) as well as its predictors and correlates, we conducted a systematic review and meta-analysis of observational studies. METHODS Our protocol was registered with PROSPERO, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology reporting standards were followed. We searched MEDLINE, Embase, and Web of Science. We used a double arcsine transformation and random-effects models to perform our meta-analyses. We performed random-effects meta-regressions using study-level data. RESULTS Our search strategy identified 10,794 abstracts. Of these, 103 articles met our eligibility criteria. There was high interstudy heterogeneity and risk of bias. The cumulative incidence of DRE was 25.0% (95% confidence interval [CI]: 16.8-34.3) in child studies but 14.6% (95% CI: 8.8-21.6) in adult/mixed age studies. The prevalence of DRE was 13.7% (95% CI: 9.2-19.0) in population/community-based populations but 36.3% (95% CI: 30.4-42.4) in clinic-based cohorts. Meta-regression confirmed that the prevalence of DRE was higher in clinic-based populations and in focal epilepsy. Multiple predictors and correlates of DRE were identified. The most reported of these were having a neurologic deficit, an abnormal EEG, and symptomatic epilepsy. The most reported genetic predictors of DRE were polymorphisms of the ABCB1 gene. CONCLUSIONS Our observations provide a basis for estimating the incidence and prevalence of DRE, which vary between populations. We identified numerous putative DRE predictors and correlates. These findings are important to plan epilepsy services, including epilepsy surgery, a crucial treatment option for people with disabling seizures and DRE.
Collapse
Affiliation(s)
- Bushra Sultana
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Marie-Andrée Panzini
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Ariane Veilleux Carpentier
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Jacynthe Comtois
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Bastien Rioux
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Geneviève Gore
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Prisca R Bauer
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Churl-Su Kwon
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Nathalie Jetté
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Colin B Josephson
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada
| | - Mark R Keezer
- From the Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM) (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.); Department of Neurosciences (B.S., M.-A.P., A.V.C., J.C., B.R., M.R.K.), Université de Montréal, Quebec; Schulich Library of Physical Sciences (G.G.), Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada; Department of Psychosomatic Medicine and Psychotherapy (P.R.B.), University Medical Center Freiburg, Germany; Department of Neurology (C.-S.K., N.J.), Icahn School of Medicine at Mount Sinai, New York; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J., C.B.J.), University of Calgary, Alberta; and School of Public Health of the Université de Montréal (M.R.K.), Quebec, Canada.
| |
Collapse
|